Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 120,664

Document Document Title
WO/2016/156396A1
Diphenethylamine derivatives for use as highly active analgesics, diuretics, anxiolytics, for the treatment of neurodegenerative, psychiatric and neuropsychiatric disorders, and also as anti- itch, anti-addiction, anti-inflammatory, anti...  
WO/2016/155661A1
Provided is a compound capable of being used to treat diseases caused by cell proliferation and/or angiogenesis or diseases associated with or accompanied by the cell proliferation and/or the angiogenesis.  
WO/2016/155545A1
Disclosed are a sulfamyl-containing 1,2,5-oxadiazole derivative, a preparation method therefor, and a use thereof in pharmaceuticals. Specifically disclosed are a sulfamyl-containing 1,2,5-oxadiazole derivative of generic formula (I), a ...  
WO/2016/160542A1
The invention provides compositions and methods for treating seizure disorders such as epilepsy in humans and animals using, the combination of a non-barbiturate anti-epileptic drug (NAED), phytocannabinoid cannabidiol (CBD); and a lipop...  
WO/2016/159082A1
The purpose of the present invention is to provide a novel compound having ACC2 inhibition activity and to provide a pharmaceutical composition containing the compound. Provided are a compound represented by formula (I) and a pharmaceuti...  
WO/2016/159335A1
Provided is a means for reducing adverse effects of a high glucose concentration on the living body. Provided are: a preparation for protecting glucose-sensitive cells from glucose toxicity caused by a high glucose concentration, the pre...  
WO/2016/154682A1
The present invention relates to methods for predicting a risk of cognitive deterioration, monitoring progression of cognitive deterioration and diagnosing cognitive deterioration in a patient. The present invention further relates to me...  
WO/2016/157053A1
A pharmaceutical composition or dietary supplement effective in the treatment of neuropathies and/or neuropathic pain is described, which comprises, as the active ingredients, the combination of curcumin, N-acetyl-L-carnitine and alpha-l...  
WO/2016/155888A1
The present invention relates to novel compounds of the formula I, methods for their preparation and their use for treatment of diseases. The invention discloses the synthesis of levodopa (L-DOPA) esters by coupling polyhydroxy compounds...  
WO/2016/160885A1
The invention describes membrane permeable creatine phosphate analog prodrugs, pharmaceutical compositions comprising membrane permeable creatine phosphate analog prodrugs, and methods of treating diseases such as ischemia, heart failure...  
WO/2016/159695A1
The present invention relates to a composition for preventing or treating an autoimmune disease, containing Ssu72 as an active ingredient. According to the present invention, Ssu72 has an effect of effectively inhibiting STAT3 activity, ...  
WO/2016/161343A3
The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; an...  
WO/2016/159256A1
A pharmaceutical composition for the treatment or prevention of neurodegenerative diseases, the pharmaceutical composition having as an active ingredient an RXR agonist that is a compound represented by formula (1) or formula (2). This p...  
WO/2016/158956A1
Provided is a compound having an MAGL inhibitory effect, and expected to be useful as an agent for the prevention or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Hutchinson's disease, amyotroph...  
WO/2016/154683A1
A method of managing pain in an individual including the following steps: providing an individual in need of pain management; administering an anti-P2X7 receptor antibody to the individual; thereby managing pain in the individual.  
WO/2016/151265A1
The invention relates to a combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3H-[1, 3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione, of the following formula [I], or one of the acid addition salts or pharmaceutically ac...  
WO/2016/150936A1
The present invention refers to new purified compositions of long chain polyunsaturated fatty acids, or their salts or esters, characterized by being essentially free from other usually present - but structurally different - components, ...  
WO/2016/149765A1
The present disclosure relates generally to compounds having activity as voltage-gated sodium channel blockers and their use in the field of therapeutic treatment, including the therapy or management of conditions associated with excessi...  
WO/2016/152953A1
The objective of the present invention is to provide an analgesic drug that is a peripherally selective opioid κ-receptor agonist and reduces side effects based on opioid μ-receptor agonists such as drug dependency and respiratory depr...  
WO/2016/150481A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to treat or prevent amyloid-related diseases, including Alzheimer disease.  
WO/2016/152054A1
Provided are compositions by which problems of free-type ω3 fatty acids or ethyl ester-type ω3 fatty acids can be overcome. The present invention provides a medicinal composition and an edible composition for preventing and/or treating...  
WO/2016/153023A1
Provided is an amyloid fiber formation inhibitor comprising a compound represented by general formulas (I)-(III): (in the formulas, Q represents -C(=O)- or the like; X represents -C(=O)-, -NH-C(=O)-, or the like; Y represents -(CH2)m-, o...  
WO/2016/152519A1
Provided is an external medicine for diffuse plexiform neurofibroma. The external medicine for diffuse plexiform neurofibroma according to the present invention comprises as an active ingredient at least one member selected from the grou...  
WO/2016/151484A1
This invention relates to new inhibitors of butyrylcholinesterase with general formulas I and II, where substituents are described in patent description. Compounds can be in the form of pure enantiomers or as racemic mixtures, or in the ...  
WO/2016/154031A1
Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with ...  
WO/2016/151132A1
The invention relates to the use of biotin for treating Amyotrophic Lateral Sclerosis, as well as demyelinating peripheral neuropathies and Neuromyelitis optica (NMO).  
WO/2016/150785A1
The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres...  
WO/2016/150971A1
The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7, to compositions conta...  
WO/2016/153957A3
Disclosed herein are methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases, such as stroke, amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, Parkinson...  
WO/2016/152952A1
The purpose of the present invention is to provide a compound having a potent analgesic effect on pain, particularly neuropathic pain. The present invention provides a cyclic amine derivative typified by chemical formula (1) or a pharmac...  
WO/2016/154522A1
This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation...  
WO/2016/153948A1
The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the ...  
WO/2016/153065A1
A method for producing a DHA-containing glyceride-containing composition, said method including a step for obtaining a DHA-containing glyceride composition by conducting an esterification reaction by causing a lipase to act on starting m...  
WO/2016/152955A1
The purpose of the present invention is to provide a compound having a potent analgesic effect on pain, particularly neuropathic pain and/or fibromyalgia. The present invention provides a cyclic amine derivative typified by chemical form...  
WO/2016/153453A1
The present invention is related to a use of Adipokinetic hormone/Red pigment- concentrating hormone (AKH/RPCH) family of peptides. The current invention particularly relates to Adipokinetic hormone/Red pigment-concentrating hormone (AKH...  
WO/2016/150403A1
A method of treating and/or preventing neurological conditions, comprising administering to a subject in need thereof a therapeutically effective amount of a p75 extracellular domain (p75ECD) or a functional fragment, variant, analogue o...  
WO/2016/151483A1
This invention relates to new inhibitors of chymothrypsin-like activity of the immunoproteasome (inhibitors of β5ί or LMP7 subunit) with the general formula (I), where substituents are described in patent description. Compounds can be ...  
WO/2016/154434A1
In alternative embodiments, provided are selective agonists having a high affinity for the alpha7 nicotinic acetylcholine receptor (α7 nAChR), assays for selectivity of nicotinic receptor subtype and ligand-gated ion channel subtype bas...  
WO/2016/152846A1
The purpose of the present invention is to provide a composition for improving circadian rhythm that can be safely taken over a long time, in particular, a composition for controlling circadian rhythm that is capable of increasing circad...  
WO/2016/154329A3
The invention provides p38 MAPK inhibitors that compensate for a frataxin deficiency or mutation and methods of using the same (e.g., to treat Friedreichs ataxia).  
WO/2016/151328A1
The present invention relates to a process for preparing serotonin reuptake inhibitors of formula (I) and pharmaceutically acceptable salts thereof, (Formula (I)) wherein, R1, R2, R3, l, m, n and Z are as defined in the specification.  
WO/2016/148263A1
The problem addressed by the present invention is to provide a pharmaceutical solid preparation which comprises stabilized [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6 -yl]acetic acid monobenzene sulfonate, and to provide...  
WO/2016/149437A1
Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: -(CR3R3)2-5-, -(CR3R3)x-Y-(CR3R3)y-, -Y-(CR3R3)2-3-Y-, -CR3R3-Y-(CR3R3)2-Y-,-Y-(CR3R3)2-Y-CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein....  
WO/2016/146583A1
The present invention relates to a compound of the general formula (II) or a salt or solvate thereof, as well as medical uses involving them, wherein A1 is selected from the group consisting of N and C-R8; A2 is selected from the group c...  
WO/2016/147144A1
A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The 5 invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the us...  
WO/2016/149401A2
Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and composition...  
WO/2016/147185A1
Novel adenosine 5'-thiophosphate derivatives, represented by Formulae (I) or (I*), and salts thereof, represented by Formulae (Ia) and (I*a), as defined in the specification, and uses thereof as antioxidants and/or P2Y1-R agonists, and/o...  
WO/2016/148264A1
The problem addressed by the present invention is to provide a pharmaceutical solid preparation which comprises stabilized [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6 -yl]acetic acid monobenzene sulfonate, and to provide...  
WO/2016/148114A1
The invention of the present application can provide: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which can achieve a definitive treatment, i.e., the inhibition of cell death, rather than conventio...  
WO/2016/149092A1
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injec...  

Matches 501 - 550 out of 120,664